...
首页> 外文期刊>Neuropsychopharmacology >Allelic Variation in the Serotonin Transporter Promoter Affects Onset of Paroxetine Treatment Response in Late-Life Depression
【24h】

Allelic Variation in the Serotonin Transporter Promoter Affects Onset of Paroxetine Treatment Response in Late-Life Depression

机译:血清素转运蛋白启动子的等位基因变异影响晚期抑郁症中帕罗西汀治疗反应的发作

获取原文
   

获取外文期刊封面封底 >>

       

摘要

The relationship of the serotonin transporter gene promoter region polymorphism (5-HTTLPR) to antidepressant response was examined in 95 elderly patients receiving a protocolized treatment for depression with paroxetine or nortriptyline. Patients were treated for up to 12 weeks and assessed weekly with clinical ratings and measurements of plasma drug concentrations. Twenty-one of the paroxetine-treated subjects were found to have the ll genotype and 30 had at least one s allele. There were no baseline differences between these groups in pretreatment Hamilton Rating Scale for Depression (HRSD) scores or anxiety symptoms. During acute treatment with paroxetine, mean reductions from baseline in HRSD were significantly more rapid for patients with the ll genotype than for those possessing an s allele, despite equivalent paroxetine concentrations. Onset of response to nortriptyline was not affected. Allelic variation of 5-HTTLPR may contribute to the variable initial response of patients treated with a selective serotonin reuptake inhibitor.
机译:在接受方案治疗的帕罗西汀或去甲替林治疗的95名老年患者中,检查了5-羟色胺转运蛋白基因启动子区多态性(5-HTTLPR)与抗抑郁反应的关系。对患者进行了长达12周的治疗,并每周进行临床评估和血浆药物浓度的评估。发现21名接受帕罗西汀治疗的受试者具有ll基因型,30名具有至少一个s等位基因。在治疗前的汉密尔顿抑郁量表评分或焦虑症状方面,这些组之间没有基线差异。在帕罗西汀的急性治疗期间,尽管帕罗西汀的浓度相等,但ll基因型患者的HRSD从基线的平均下降明显快于那些拥有s等位基因的患者。对去甲替林的反应发作不受影响。 5-HTTLPR的等位基因变异可能与选择性5-羟色胺再摄取抑制剂治疗的患者的初始反应不同有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号